Amgen (NASDAQ:AMGN) Issues Quarterly Earnings Results

Amgen (NASDAQ:AMGN) issued its earnings results on Tuesday. The medical research company reported $6.45 earnings per share for the quarter, topping the consensus estimate of $5.79 by $0.66, FiscalAI reports. The firm had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $4.19 on Tuesday, hitting $461.26. The company’s stock had a trading volume of 2,309,446 shares, compared to its average volume of 2,743,839. The company has a market capitalization of $249.37 billion, a price-to-earnings ratio of 28.67, a price-to-earnings-growth ratio of 3.31 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen has a 12 month low of $294.48 and a 12 month high of $475.64. The stock’s 50-day moving average is $420.49 and its two-hundred day moving average is $375.49.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. Amgen’s dividend payout ratio is presently 62.65%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of a number of analyst reports. Bank of America increased their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Sanford C. Bernstein lifted their price objective on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. TD Cowen boosted their target price on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. BMO Capital Markets decreased their target price on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research report on Monday, October 12th. Finally, Scotiabank raised their price target on shares of Amgen from $450.00 to $500.00 and gave the company an “outperform” rating in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $389.71.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported third-quarter adjusted earnings of $6.45 per share, beating the $5.79 consensus estimate, while revenue of $10.37 billion also topped expectations of $10.07 billion. Amgen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Separate coverage highlighted data showing Amgen’s Imdelltra, combined with AstraZeneca’s Imfinzi, reduced the risk of death by 58% in patients with advanced lung cancer. The findings could support the drug’s growth potential, subject to further clinical and regulatory progress. Amgen Just Gave Its Shareholders Great News
• Negative Sentiment: An FDA warning letter over allegedly misleading promotion of Vectibix raises regulatory and reputational concerns, potentially offsetting some of the positive reaction to the earnings beat. Amgen Gets FDA Warning Letter Over Vectibix Promotion

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.